Clinigene International, a wholly-owned subsidiary of Biocon, and Scirex Corporation, a wholly-owned subsidiary of the Omnicom Group, have signed a letter of intent (LoI) to collaborate on global clinical trials.
According to a release issued by Biocon to the BSE today, the LoI was signed at the headquarters of Scirex in Pennsylvania, USA, during a recent visit by Kiran Mazumdar-Shaw, CMD of Biocon, and Arvind Atignal, COO of Clinigene.
"With India rapidly emerging as a key locale for clinical research, the new relationship provides Scirex clients immediate access to well developed expertise in clinical investigation in India, and provides Clinigene the opportunity to expand its markets and partake in global clinical trial programmes," the release added.
Mazumdar-Shaw said that she saw the partnership as a natural evolution for Clinigene and Biocon given the "significant investment made over the past decade in systems, processes and people. We are proud of the leading role we have taken in India and look forward to enabling Scirex's clients to benefit from the quality and speed of clinical development in India." |
Content Guide
